Colorectal cancer
1L+ MSI-H/d-MMR metastatic/recurrent CRC1
Colorectal cancer
1L+ MSI-H/d-MMR metastatic/recurrent CRC1
1L setting1
2L+ setting2
Click to zoom 
*In all settings, nivolumab monotherapy should be initiated 3 weeks following the last dose of the combination of nivolumab and ipilimumab.1
1L, first-line; 1L+, first-line or later; 2L+, second-line or later; CRC, colorectal cancer; d-MMR, mismatch repair deficient; IV, intravenous; MSI-H, high microsatellite instability; QxW, every x weeks.
1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb.
2. Yervoy® (ipilimumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb.
